It's time for the Lightning Round. Cramer makes the call on viewer favorites.» Read More
If you were ever needed examples of the phenomenal risk and reward of investing in baby biopharma look no further than what’s going on in the sector today.
Investors are placing their bets on the next M&A deal in biotech. Where should you be looking?
What a week! And there's still one day left. Human Genome Sciences and Orexigen got the party started on Monday with their Lupus and diet drug data, respectively. Onyx Pharmaceuticals was a surprise guest with its mid-stage breast cancer results on Wednesday. Bristol-Myers Squibb cranked up the volume late yesterday with its two-bagger for Medarex. And then this morning Celgene announced it had stopped a multiple myeloma study early because the drug appears to be working so well.
With the markets selling off again today, CNBC asked the experts for their best investment ideas now.
The Lightning Round is extended in this new CNBC.com exclusive feature.
For quite some time now analysts and investors have been speculating that big pharma would go on a biotech buying binge. So, will the announcement by Biogen Idec late Friday that it's putting itself on the market be the spark that ignites an M & A explosion in the sector? Perhaps.
While on Capitol Hill the new Congress begins to take on the pharmaceuticals industry, the healthcare investment community is holding its annual confab in the hills of San Francisco--House Speaker Nancy Pelosi's home district. I'm at the 25th Annual JPMorgan Healthcare Conference at the Westin St. Francis on Union Square. The four-day event is just getting started, but the halls are...